144 related articles for article (PubMed ID: 15826554)
1. [Toxic epidermal necrolysis associated with abacavir].
Montero M; García-Gibert L; Giménez-Arnau AM; Knobel H
Enferm Infecc Microbiol Clin; 2005 Apr; 23(4):247. PubMed ID: 15826554
[No Abstract] [Full Text] [Related]
2. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)-induced Stevens-Johnson syndrome and gynecomastia in an HIV-infected child: A case report.
Saka B; Akakpo AS; Bassowa A; Dapam AN; Mahamadou G; Teclessou JN; Mouhari-Toure A; Laouali AY; Mensah E; Kombaté K; Pitché P
Ann Dermatol Venereol; 2018 Dec; 145(12):773-776. PubMed ID: 30301570
[TBL] [Abstract][Full Text] [Related]
3. A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II).
Eron JJ; Murphy RL; Peterson D; Pottage J; Parenti DM; Jemsek J; Swindells S; Sepulveda G; Bellos N; Rashbaum BC; Esinhart J; Schoellkopf N; Grosso R; Stevens M
AIDS; 2000 Jul; 14(11):1601-10. PubMed ID: 10983647
[TBL] [Abstract][Full Text] [Related]
4. Heart attack risk with abacavir and didanosine.
AIDS Patient Care STDS; 2008 Apr; 22(4):346-7. PubMed ID: 18434947
[No Abstract] [Full Text] [Related]
5. Replacing stavudine by abacavir reduces lactate levels and may improve lipoatrophy.
García-Benayas T; Blanco F; de la Cruz JJ; Soriano V; González-Lahoz J
AIDS; 2003 Apr; 17(6):921-4. PubMed ID: 12660543
[No Abstract] [Full Text] [Related]
6. Stavudine plus didanosine and nevirapine in antiretroviral-naive HIV-infected adults: preliminary safety and efficacy results. VIRGO Study Team.
Raffi F; Reliquet V; Francois C; Garre M; Hascoet C; Allavena C; Arvieux C; Breux JP; Perre P; Rozenbaum W; Auger S
Antivir Ther; 1998; 3 Suppl 4():57-60. PubMed ID: 10723512
[TBL] [Abstract][Full Text] [Related]
7. K65R with and without S68: a new resistance profile in vivo detected in most patients failing abacavir, didanosine and stavudine.
Røge BT; Katzenstein TL; Obel N; Nielsen H; Kirk O; Pedersen C; Mathiesen L; Lundgren J; Gerstoft J
Antivir Ther; 2003 Apr; 8(2):173-82. PubMed ID: 12741630
[TBL] [Abstract][Full Text] [Related]
8. Stavudine, didanosine and nevirapine in antiretroviral-naive HIV-1-infected patients.
Reliquet V; Ferré V; Hascoet C; Besnier JM; Bellein V; Arvieux C; Molina JM; Breux JP; Zucman D; Rozenbaum W; Allavena C; Raffi F;
Antivir Ther; 1999; 4 Suppl 3():83-4. PubMed ID: 16021876
[TBL] [Abstract][Full Text] [Related]
9. Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis.
Fagot JP; Mockenhaupt M; Bouwes-Bavinck JN; Naldi L; Viboud C; Roujeau JC;
AIDS; 2001 Sep; 15(14):1843-8. PubMed ID: 11579247
[TBL] [Abstract][Full Text] [Related]
10. Comparison of two once-daily regimens with a regimen consisting of nelfinavir, didanosine, and stavudine in antiretroviral therapy-naïve adults: 48-week results from the Antiretroviral Regimen Evaluation Study (ARES).
Lowe SH; Wensing AM; Hassink EA; ten Kate RW; Richter C; Schreij G; Koopmans PP; Juttmann JR; van der Tweel I; Lange JM; Borleffs JC
HIV Clin Trials; 2005; 6(5):235-45. PubMed ID: 16306030
[TBL] [Abstract][Full Text] [Related]
11. Sweet's syndrome following abacavir therapy.
Del Giudice P; Vandenbos F; Perrin C; Bernard E; Marq L; Dellamonica P
J Am Acad Dermatol; 2004 Sep; 51(3):474-5. PubMed ID: 15337997
[No Abstract] [Full Text] [Related]
12. [Exanthema in a patient infected with the human immunodeficiency virus after starting antiretroviral treatment].
Palacios Muñoz R; Santos González J; Bosch García R; Márquez Solero M
Rev Clin Esp; 2000 Nov; 200(11):635-6. PubMed ID: 11196597
[No Abstract] [Full Text] [Related]
13. Protease inhibitor-sparing regimen suppresses HIV.
AIDS Patient Care STDS; 1998 Dec; 12(12):940. PubMed ID: 11362068
[No Abstract] [Full Text] [Related]
14. Chronic cough induced by abacavir apart from a context of hypersensitivity.
Peyrière H; Mauboussin JM; Arnaud A; Rouanet I; Vincent D
Allerg Immunol (Paris); 2002 Dec; 34(10):359-60. PubMed ID: 12575618
[TBL] [Abstract][Full Text] [Related]
15. [A short-term trial of Didanosine, stavudine, and nevirapine combination therapy for human immunodeficiency virus infection].
Zheng YH; Yang X; Chang WH
Hunan Yi Ke Da Xue Xue Bao; 2003 Aug; 28(4):390. PubMed ID: 14653126
[No Abstract] [Full Text] [Related]
16. Long-term safety and efficacy of nevirapine, stavudine and lamivudine in a real-world setting.
Shalit P; Farrell P; Lindgren P
AIDS; 2001 Apr; 15(6):804-5. PubMed ID: 11371699
[No Abstract] [Full Text] [Related]
17. Managing HIV lipoatrophy.
Moyle G; Sutinen J
Lancet; 2004 Feb; 363(9407):412-4. PubMed ID: 14962517
[No Abstract] [Full Text] [Related]
18. Clinical and laboratory signs of mitochondrial dysfunction secondary to nucleoside analogue antiretroviral therapy are reversible.
Hagberg L; Janson GL
Scand J Infect Dis; 2001; 33(7):558. PubMed ID: 11515773
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of two different triple drug combinations in which either lamivudine or didanosine were administered with stavudine plus indinavir.
Villalba N; Gómez-Cano M; Casas E; Soriano V; Valencia E; González-Lahoz J
AIDS; 1997 Dec; 11(15):1896-7. PubMed ID: 9412717
[No Abstract] [Full Text] [Related]
20. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study.
Martin A; Smith DE; Carr A; Ringland C; Amin J; Emery S; Hoy J; Workman C; Doong N; Freund J; Cooper DA;
AIDS; 2004 Apr; 18(7):1029-36. PubMed ID: 15096806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
